Plasma surfactant protein-D, matrix metalloproteinase-7, and osteopontin index distinguishes idiopathic pulmonary fibrosis from other idiopathic interstitial pneumonias

American Journal of Respiratory and Critical Care Medicine

Volumn 194, Issue 10, 2016, Pages 1242-1251

  White, Eric S ^a   Xia, Meng ^b   Murray, Susan ^b   Dyal, Rachel ^a   Flaherty, Candace M ^a   Flaherty, Kevin R ^a   Moore, Bethany B ^a   Cheng, Ling ^c   Doyle, Tracy J ^d   Villalba, Julian ^d   Dellaripa, Paul F ^e   Rosas, Ivan O ^d   Kurtis, Jonathan D ^c   Martinez, Fernando J ^f  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN SCHOOL OF PUBLIC HEALTH   (United States)

^c BROWN UNIVERSITY   (United States)

^d Division of Pulmonary and Critical Care   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Biomarker; Fibrosis; Plasma

Indexed keywords

CARBON MONOXIDE; COLLAGEN TYPE 1; COLLAGEN TYPE 4; COLLAGEN TYPE 6; ENDOTHELIN 1; FIBRONECTIN; MATRILYSIN; OSTEOGENIC PROTEIN 1; OSTEOPONTIN; PROCOLLAGEN; PROCOLLAGEN 1; PYRIDINOLINE; SURFACTANT PROTEIN D; UNCLASSIFIED DRUG; BIOLOGICAL MARKER;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIFFERENTIAL DIAGNOSIS; EXTRACELLULAR MATRIX; FEMALE; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; HUMAN; HUMAN TISSUE; INTERSTITIAL PNEUMONIA; LUNG BIOPSY; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS; SENSITIVITY AND SPECIFICITY; VALIDATION STUDY; BLOOD; RECEIVER OPERATING CHARACTERISTIC;

BIOMARKERS; COHORT STUDIES; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; IDIOPATHIC INTERSTITIAL PNEUMONIAS; IDIOPATHIC PULMONARY FIBROSIS; MALE; MATRIX METALLOPROTEINASE 7; MIDDLE AGED; OSTEOPONTIN; PULMONARY SURFACTANT-ASSOCIATED PROTEIN D; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 84998814253     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201505-0862OC     Document Type: Article

References (41)

1. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, et al.; ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011;183:788-824.
2. Raghu G, Selman M. Nintedanib and pirfenidone. New antifibrotic treatments indicated for idiopathic pulmonary fibrosis offer hopes and raises questions. Am J Respir Crit Care Med 2015;191: 252-254.
3. Raghu G, Anstrom KJ, King TE Jr, Lasky JA, Martinez FJ; Idiopathic Pulmonary Fibrosis Clinical Research Network. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med 2012;366:1968-1977.
4. Kondoh Y, Taniguchi H, Kitaichi M, Yokoi T, Johkoh T, Oishi T, Kimura T, Nishiyama O, Kato K, du Bois RM. Acute exacerbation of interstitial pneumonia following surgical lung biopsy. Respir Med 2006;100: 1753-1759.
5. Thomeer M, Demedts M, Behr J, Buhl R, Costabel U, Flower CD, Verschakelen J, Laurent F, Nicholson AG, Verbeken EK, et al.; Idiopathic Pulmonary Fibrosis International Group Exploring N-Acetylcysteine I Annual (IFIGENIA) Study Group. Multidisciplinary interobserver agreement in the diagnosis of idiopathic pulmonary fibrosis. Eur Respir J 2008;31:585-591.
6. Thannickal VJ. Mechanisms of pulmonary fibrosis: role of activated myofibroblasts and NADPH oxidase. Fibrogenesis Tissue Repair 2012;5:S23.
7. Thannickal VJ, Henke CA, Horowitz JC, Noble PW, Roman J, Sime PJ, Zhou Y, Wells RG, White ES, Tschumperlin DJ. Matrix biology of idiopathic pulmonary fibrosis: a workshop report of the National Heart, Lung, and Blood Institute. Am J Pathol 2014;184: 1643-1651.
8. Booth AJ, Hadley R, Cornett AM, Dreffs AA, Matthes SA, Tsui JL, Weiss K, Horowitz JC, Fiore VF, Barker TH, et al. Acellular normal and fibrotic human lung matrices as a culture system for in vitro investigation. Am J Respir Crit Care Med 2012;186:866-876.
9. Fell CD, Martinez FJ, Liu LX, Murray S, Han MK, Kazerooni EA, Gross BH, Myers J, Travis WD, Colby TV, et al. Clinical predictors of a diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2010;181:832-837.
10. Marinković A, Liu F, Tschumperlin DJ. Matrices of physiologic stiffness potently inactivate idiopathic pulmonary fibrosis fibroblasts. Am J Respir Cell Mol Biol 2013;48:422-430.
11. Parker MW, Rossi D, Peterson M, Smith K, Sikström K, White ES, Connett JE, Henke CA, Larsson O, Bitterman PB. Fibrotic extracellular matrix activates a profibrotic positive feedback loop. J Clin Invest 2014;124:1622-1635.
12. Selman M, Ruiz V, Cabrera S, Segura L, Raḿirez R, Barrios R, Pardo A. TIMP-1,-2,-3, and-4 in idiopathic pulmonary fibrosis. A prevailing nondegradative lung microenvironment? Am J Physiol Lung Cell Mol Physiol 2000;279:L562-L574.
13. Vuga LJ, Milosevic J, Pandit K, Ben-Yehudah A, Chu Y, Richards T, Sciurba J, Myerburg M, Zhang Y, Parwani AV, et al. Cartilage oligomeric matrix protein in idiopathic pulmonary fibrosis. PLoS One 2013;8:e83120.
14. Pardo A, Gibson K, Cisneros J, Richards TJ, Yang Y, Becerril C, Yousem S, Herrera I, Ruiz V, Selman M, et al. Up-regulation and profibrotic role of osteopontin in human idiopathic pulmonary fibrosis. PLoS Med 2005;2:e251.
15. Pardo A, Selman M, Raḿirez R, Ramos C, Montaño M, Stricklin G, Raghu G. Production of collagenase and tissue inhibitor of metalloproteinases by fibroblasts derived from normal and fibrotic human lungs. Chest 1992;102:1085-1089.
16. Pardo A, Selman M. Decreased collagenase production by fibroblasts derived from idiopathic pulmonary fibrosis. Matrix Suppl 1992;1:417-418.
17. Rosas IO, Richards TJ, Konishi K, Zhang Y, Gibson K, Lokshin AE, Lindell KO, Cisneros J, Macdonald SD, Pardo A, et al. MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis. PLoS Med 2008;5:e93.
18. Kropski JA, Pritchett JM, Zoz DF, Crossno PF, Markin C, Garnett ET, Degryse AL, Mitchell DB, Polosukhin VV, Rickman OB, et al. Extensive phenotyping of individuals at risk for familial interstitial pneumonia reveals clues to the pathogenesis of interstitial lung disease. Am J Respir Crit Care Med 2015;191:417-426.
19. Allam JS, Kottom TJ, Vuk-Pavlovic Z, Limper AH. Biomarkers in idiopathic pulmonary fibrosis: a lung tissue research consortium based study. Am J Respir Crit Care Med 2008;177:A46.
20. Honda Y, Kuroki Y, Matsuura E, Nagae H, Takahashi H, Akino T, Abe S. Pulmonary surfactant protein D in sera and bronchoalveolar lavage fluids. Am J Respir Crit Care Med 1995;152:1860-1866.
21. McDonald EA, Cheng L, Jarilla B, Sagliba MJ, Gonzal A, Amoylen AJ, Olveda R, Acosta L, Baylink D, White ES, et al. Maternal infection with Schistosoma japonicum induces a profibrotic response in neonates. Infect Immun 2014;82:350-355.
22. Fabre V, Wu H, PondTor S, Coutinho H, Acosta L, Jiz M, Olveda R, Cheng L, White ES, Jarilla B, et al. Tissue inhibitor of matrix-metalloprotease-1 predicts risk of hepatic fibrosis in human Schistosoma japonicum infection. J Infect Dis 2011;203:707-714.
23. Greenhouse SW, Mantel N. The evaluation of diagnostic tests. Biometrics 1950;6:399-412.
24. Youden WJ. Index for rating diagnostic tests. Cancer 1950;3:32-35.
25. Deng H, Wickham H. Density estimation in R. 2011 [accessed 2016 Jan 4]. Available from: http://cosc.uh.edu/zceick/7362/T2-4.pdf
26. Armitage P. Tests for linear trends in proportions and frequencies. Biometrics 1955;11:375-386.
27. Cochran WG. Some methods for strengthening the common chi-squared tests. Biometrics 1954;10:417-451.
28. Yuen KK. The two-sample trimmed t for unequal population variances. Biometrica 1974;61:165-170.
29. Pardo A, Selman M. Extracellular matrix remodeling in idiopathic pulmonary fibrosis. Chest 2001;120:S77-S77S.
30. Takahashi H, Fujishima T, Koba H, Murakami S, Kurokawa K, Shibuya Y, Shiratori M, Kuroki Y, Abe S. Serum surfactant proteins A and D as prognostic factors in idiopathic pulmonary fibrosis and their relationship to disease extent. Am J Respir Crit Care Med 2000;162:1109-1114.
31. Takahashi F, Takahashi K, Okazaki T, Maeda K, Ienaga H, Maeda M, Kon S, Uede T, Fukuchi Y. Role of osteopontin in the pathogenesis of bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol 2001;24:264-271.
32. Lee SH, Seo GS, Park YN, Yoo TM, Sohn DH. Effects and regulation of osteopontin in rat hepatic stellate cells. Biochem Pharmacol 2004; 68:2367-2378.
33. Jovic S, Shikhagaie M, Mörgelin M, Erjefält JS, Kjellström S, Egesten A. Osteopontin is increased in cystic fibrosis and can skew the functional balance between ELR-positive and ELR-negative CXC-chemokines. J Cyst Fibros 2015;14:453-463.
34. López B, González A, Lindner D, Westermann D, Ravassa S, Beaumont J, Gallego I, Zudaire A, Brugnolaro C, Querejeta R, et al. Osteopontin-mediated myocardial fibrosis in heart failure: a role for lysyl oxidase? Cardiovasc Res 2013;99:111-120.
35. Nagao T, Okura T, Irita J, Jotoku M, Enomoto D, Desilva VR, Miyoshi K, Kurata M, Matsui Y, Uede T, et al. Osteopontin plays a critical role in interstitial fibrosis but not glomerular sclerosis in diabetic nephropathy. Nephron Extra 2012;2:87-103.
36. Wang X, Lopategi A, Ge X, Lu Y, Kitamura N, Urtasun R, Leung TM, Fiel MI, Nieto N. Osteopontin induces ductular reaction contributing to liver fibrosis. Gut 2014;63:1805-1818.
37. Binder M, Christoph S, Sehnert B, Uhl M, Peter HH, Voll RE, Warnatz K, Kollert F. Elevated serum osteopontin levels in idiopathic retroperitoneal fibrosis. Clin Exp Rheumatol 2012;30:772-775.
38. Matsue Y, Tsutsumi M, Hayashi N, Saito T, Tsuchishima M, Toshikuni N, Arisawa T, George J. Serum osteopontin predicts degree of hepatic fibrosis and serves as a biomarker in patients with hepatitis C virus infection. PLoS One 2015;10:e0118744.
39. Jenkins RG, Simpson JK, Saini G, Bentley JH, Russell AM, Braybrooke R, Molyneaux PL, McKeever TM, Wells AU, Flynn A, et al. Longitudinal change in collagen degradation biomarkers in idiopathic pulmonary fibrosis: an analysis from the prospective, multicentre PROFILE study. Lancet Respir Med 2015;3:462-472.
40. Raghu G, Lynch D, Godwin JD, Webb R, Colby TV, Leslie KO, Behr J, Brown KK, Egan JJ, Flaherty KR, et al. Diagnosis of idiopathic pulmonary fibrosis with high-resolution CT in patients with little or no radiological evidence of honeycombing: secondary analysis of a randomised, controlled trial. Lancet Respir Med 2014;2:277-284.
41. Restrepo JF, del Rincón I, Battafarano DF, Haas RW, Doria M, Escalante A. Clinical and laboratory factors associated with interstitial lung disease in rheumatoid arthritis. Clin Rheumatol 2015; 34:1529-1536.